Contact us
Young GI
Patients
Industry
Press
My Connect
Create myUEG account
About
To landing page
Who we are
Boards, Committees & Groups
Governance
Headquarters Management
History
What we do
Strategic Drivers
Year in Review
Our Members
Specialist Member Societies
National Member Societies
myUEG Community
myUEG Associates
My Connect
Women in GI
Young GIs
Researchers
Event Calendar
Week
To landing page
Attendance
Registration fees
Hotel
Venue
Eco-friendly info
Programme
Abstract Submission
Postgraduate Teaching
Nurse Programme
Hands-on
Industry Programme
Acknowledgements
CME Accreditation
UEG Week on-demand
Congress Resources
Education
To landing page
Online Education
Online Courses
Webinars
Career Development
Face-to-face Education
Summer School
Masterclass
Clinical Visiting Fellowships
Education Resources
Mistakes in...
UEG Talks Podcast
Image Hub
CME in Europe
Event Endorsement
Supporters
Research
To landing page
Support
Horizon Europe Support
Projects
Research Prize
Research Fellowship
Research Webinars
Advocacy
Position Papers
White Book 2
Main Results
Full Reports
Materials and Presentations
Quality of Care
To landing page
Search Guidelines
Standards & Guidelines Repository
Non-English Guidelines
GI Guidelines App
Develop & Implement
Guideline development framework
Guideline development course
Get Funding
Get Endorsement
Guideline Webinars
Projects
Quality of Care Initiatives
Quality Standards
Public Affairs
To landing page
Advocacy
Core Positions
Stakeholder Collaboration
White Book 2
Position Papers
MEP Digestive Health Group
Our Supporters
#EUNewsline →
EU Elections 2024
Publications
To landing page
Publications
Congress Publications
Research Publications
Public Affairs Publications
Education Publications
UEG Publications
UEG Journal →
UEG Journal Podcast
White Book 2
Opportunities
To landing page
Congress Opportunities
Top Abstract Prizes
National Scholar Award
Travel Grants
International Scholarship Awards
Research Funding
Research Prize
Research Fellowship
Horizon Europe Application Support
Activities Funding
Recognition of Achievements
Lifetime Achievement Award
Journal Best Paper Award
Activities Endorsement
Professional Advancement
Rising Star Awards
Clinical Visiting Fellowships
Open Positions
Talent Pool
Library
To landing page
Congress Resources
UEG Week on-demand
Abstracts
Posters
Guideline Resources
Education Resources
Image Hub
Webinars
Mistakes in... articles
Contact us
Young GI
Patients
Industry
Press
Author
Silvio Danese
EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION
Silvio Danese
et al.
ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: CHRONIC THERAPY DATA FROM THE VIBRATO UMBRELLA STUDY
Silvio Danese
et al.
TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL
Silvio Danese
et al.
NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE
Silvio Danese
et al.
SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL
Silvio Danese
et al.
ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: DATA FROM THE VIBRATO UMBRELLA STUDY
Silvio Danese
et al.
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS
Silvio Danese
et al.
EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMAB FOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OF THE PHASE 4 EARNEST TRIAL
Silvio Danese
et al.
ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY
Silvio Danese
et al.
IMPACT OF FILGOTINIB ON INDIVIDUAL INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS: POST HOC ANALYSES FROM SELECTION
Silvio Danese
et al.
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY
Silvio Danese
et al.
EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION
Silvio Danese
et al.
EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION
Silvio Danese
et al.
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations
Silvio Danese
et al.
AURICULAR TRANSCUTANEOUS STIMULATION AS AN EXPLORATORY PREOPERATIVE SCREENING TEST FOR CLINICAL RESPONSE TO VAGUS NERVE STIMULATION IN DRUG-RESISTANT CROHN’S DISEASE
Silvio Danese
et al.
IMPACT OF CONCOMITANT THIOPURINE ON THE EFFICACY AND SAFETY OF FILGOTINIB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
Silvio Danese
et al.
PRA023 IMPROVED HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY IBDQ-32 IN A PHASE 2 TRIAL FROM PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Silvio Danese
et al.
ONLINE EDUCATION SIGNIFICANTLY IMPROVED GASTROENTEROLOGISTS' KNOWLEDGE OF CROHN DISEASE MANAGEMENT
Silvio Danese
et al.
CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB – A POST HOC ANALYSIS OF SELECTION
Silvio Danese
et al.
CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS
Silvio Danese
et al.
Item 41 - 60 / 122
1
2
3
4
5
6
7
Chat with us
, powered by
LiveChat